JATT vs. CCCC, JSPR, TNYA, AURA, TRML, MGTX, STRO, AVXL, REPL, and SOPH
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include C4 Therapeutics (CCCC), Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), Tourmaline Bio (TRML), MeiraGTx (MGTX), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), Replimune Group (REPL), and SOPHiA GENETICS (SOPH). These companies are all part of the "biological products, except diagnostic" industry.
C4 Therapeutics (NASDAQ:CCCC) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
JATT Acquisition has a net margin of 0.00% compared to JATT Acquisition's net margin of -629.24%. C4 Therapeutics' return on equity of -49.58% beat JATT Acquisition's return on equity.
In the previous week, C4 Therapeutics had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for C4 Therapeutics and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.93 beat C4 Therapeutics' score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.
C4 Therapeutics presently has a consensus price target of $10.13, indicating a potential upside of 102.50%. Given JATT Acquisition's higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than JATT Acquisition.
C4 Therapeutics received 25 more outperform votes than JATT Acquisition when rated by MarketBeat users.
JATT Acquisition has lower revenue, but higher earnings than C4 Therapeutics.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
C4 Therapeutics beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
